The primary analysis compared time to all-cause death among patients with AML based on FLT3 and NPM1 mutation status, age (<65 years, ≥65 years), and cytogenetic risk group (unfavorable, intermediate/normal, favorable). Here, NPM1 is linked to acute myeloid leukemia.